Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Putting the CAR-T before the horse

This article was originally published in Scrip

Executive Summary

One of the portfolio metrics that investors worry about is the degree to which the prices of their investments are correlated with each other. Statisticians call this multicolinearity. This is because you don't want to be invested in, for example, all gene therapy companies when the next gene therapy patient develops a cancer as a result of their treatment – a falling tide will ground all your ships on the same day.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel